Application No. 10/665,936 Amd. Dated: August 27, 2007 Reply to Office Action mailed April 26, 2007

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A device for the treatment of aneurysmal tissue, comprising:

at least one reservoir; and

at least one therapeutic agent within said reservoir;

wherein said reservoir is adapted for implantation within or adjacent to an aneurysm site within a vessel lumen and delivers at least one therapeutic agent to said aneurysmal tissue for the treatment of said aneurysmal tissue.

Claim 2 (canceled).

Claim 3 (previously presented): The device of claim 73, wherein carrier is a time release carrier.

Claim 4 (original): The device of claim 3, wherein the carrier and at least one therapeutic agent are formulated as a sheet, pellets, a sponge, a slab, a gel, capsules, microspheres, nanospheres, liquids or combinations thereof.

Claim 5 (canceled):

Claim 6 (previously presented): The device of claim 1, wherein the reservoir comprises a synthetic biodegradable polymer, a synthetic biostable polymer, a natural polymer, an inorganic material or combinations thereof.

Claim 7 (original): The device of claim 6, wherein the biodegradable polymer is an aliphatic polyester, a poly(ortho ester), a poly(ester amide), a poly(ester urethane), a poly(ester anhydride), a poly(ester carbonate), a polyphosphazene, a polyarylate, a poly(ether ester), and/or combinations thereof.

Application No. 10/665,936 Amd. Dated: August 27, 2007 Reply to Office Action mailed April 26, 2007

1,

Claim 8 (original): The device of claim 7, wherein the aliphatic polyester is

poly(lactic acid), poly(glycolic acid), poly(lactic acid-co-glycolic acid), or poly(e-caprolactone)

or co-polymers thereof.

Claim 9 (original): The device of claim 6, wherein the biostable polymer is a

polyolefin, a polyurethane, a fluorinated polyolefin, a chlorinated polyolefin, a polyamide, an

acrylate polymer, an acrylamide polymer, a vinyl polymer, a polyacetal, a polycarbonate, a

polyether, an aromatic polyester, a poly(ether ether ketone), a polysulfone, a silicone rubber, a

thermoset, or a poly(ester imide) and/or combinations thereof.

Claim 10 (original): The device of claim 9, wherein the polymer is poly(butyl

methacrylate), poly(methyl methacrylate), poly(ethylene-co-vinylacetate), or poly(ethylene-co-

methylacetate) or co-polymers thereof.

Claim 11 (original): The device of claim 6, wherein the natural polymer is

albumin, collagen, gelatin, hyaluronic acid, starch, alginate, pectin, cellulose and cellulose

derivatives, casein, dextran, polysaccharides, or fibrinogen and/or combinations thereof.

Claim 12 (previously presented): The device of claim 73, wherein the carrier

comprises a synthetic biodegradable polymer, and the reservoir comprises a synthetic biostable

polymer, a natural polymer, an inorganic material or combinations thereof.

Claim 13 (canceled):

Claim 14 (canceled):

Claim 15 (original): The device of claim 1, wherein the at least one therapeutic

agent is a matrix metalloproteinase (MMP) inhibitor, an antibiotic, a cyclooxygenase-2 (COX-2)

inhibitor, an angiotensin-converting enzyme (ACE) inhibitor, a glucocorticoid, a beta blocker, a

nitric acid synthase (NOS) inhibitor, an antioxidant, an antibody, or a non-steroidal anti-

inflammatory drug (NSAID).

Claim 16 (original): The device of claim 1, wherein at least one therapeutic

comprises a combination of therapeutic agents.

Page 3 of 9

Claim 17 (previously presented): The device of claim 55, wherein the reservoir is located adjacent to said stent graft between the stent graft and the aneurysmal site.

Claim 18 (previously presented): The device of claim 1, wherein the reservoir is located inside the aneurysmal sac.

Claim 19 (previously presented): The device of claim 1, wherein the reservoir is located outside the aneurysmal sac.

Claims 20-54 (canceled).

Claim 55 (previously presented): The device of claim 1, further comprising a stent graft, said stent graft adapted to be implanted at said aneurysm site.

Claim 56-72 (canceled):

Claim 73 (previously presented): The device of claim 1 wherein said reservoir further comprises a carrier material.

Claim 74 (currently amended): [A device for the treatment of aneurismal tissue]

An aneurismal tissue treatment device, comprising:

at least one reservoir; and

at least one therapeutic agent within said reservoir;

wherein said reservoir is adapted for implantation external to an aneurysm site and delivers at least one therapeutic agent to said aneurismal tissue by means of a pump and tubing for the treatment of said aneurismal tissue[.]; and

wherein said at least one therapeutic agent is selected from the group consisting of matrix metalloproteinase (MMP) inhibitors, antibiotics such as doxycycline and tetracycline, cyclooxygenase-2 (COX-2) inhibitors, angiotensin-converting enzyme (ACE) inhibitors, glucocorticoids, beta blockers, nitric oxide synthase (NOS) inhibitors, antioxidants, non-steroidal anti-inflammatory drugs (NSAIDs) and cellular adhesion molecules (CAMs), and combinations thereof.

Claim 75 (previously presented): The device of claim 74, wherein said pump is a mechanical, electrical, or osmotic pump.

Claim 76 (currently amended): The device of claim 74, wherein a first end of said tubing is in communication with said pump and a second end of said tubing is <u>adapted to be</u> located within the blood vessel lumen within or adjacent to the aneurysm sac.

Claim 77 (new): An aneurismal tissue treatment system comprising:

a stent graft adapted for placement within a vessel lumen adjacent an aneurismal site; and

at least one implantable therapeutic agent delivery reservoir adapted to be implanted external said aneurismal site and further adapted to deliver a carrier comprising at least one therapeutic agent to said aneurismal site.

Claim 78 (new): The aneurismal tissue treatment system according to claim 77 wherein said implantable therapeutic agent delivery reservoir is a pump.

Claim 79 (new): The aneurismal tissue treatment system according to claim 77 wherein said carrier is a therapeutic agent solvent.

Claim 80 (new): The aneurismal tissue treatment system according to claim 78 wherein said pump is mechanical, electrical, or osmotic.

Claim 81 (new): The aneurismal tissue treatment system according to claim 77 further comprising a means for refilling said implantable therapeutic agent delivery reservoir with said therapeutic agent.

Claim 82 (new): The aneurismal tissue treatment system according to claim 77 wherein said at least one therapeutic agent is selected from the group consisting of matrix metalloproteinase (MMP) inhibitors, antibiotics such as doxycycline and tetracycline, cyclooxygenase-2 (COX-2) inhibitors, angiotensin-converting enzyme (ACE) inhibitors, glucocorticoids, beta blockers, nitric oxide synthase (NOS) inhibitors, antioxidants, non-steroidal

Application No. 10/665,936 Amd. Dated: August 27, 2007 Reply to Office Action mailed April 26, 2007

anti-inflammatory drugs (NSAIDs) and cellular adhesion molecules (CAMs), and combinations thereof.

Claim 83 (new): The aneurismal tissue treatment system according to claim 77 wherein said at least one implantable therapeutic agent delivery reservoir delivers said at least one therapeutic agent to said aneurismal tissue by means of a pump and tubing for the treatment of said aneurismal tissue.